MOUNTAIN VIEW, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced the Company will host its third quarter financial results conference call on November 14, 2023 and plans to participate in the upcoming Stifel Healthcare Conference on November 15, 2023 in New York, NY.
Third Quarter Earnings Conference Call
The Company’s management team will host a conference to discuss reported financial results and business updates beginning at 2:00 p.m. PT / 5:00 p.m. ET on November 14, 2023.
Stifel 2023 Healthcare Conference
Management is scheduled to present on Wednesday, November 15 at 10:20 a.m. ET.
Investors interested in listening to the conference call and presentation may do so by accessing the live and recorded webcasts on the “Event Calendar” page of the “Investors” section of the Company’s website at: www.iridex.com.
About Iridex
Iridex Corporation is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. The Company’s proprietary MicroPulse® technology delivers a differentiated treatment that provides safe, effective, and proven treatment for targeted sight-threatening eye conditions. Iridex’s current product line is used for the treatment of glaucoma and diabetic macular edema (DME) and other retinal diseases. Iridex products are sold in the United States through a direct sales force and internationally primarily through a network of independent distributors into more than 100 countries. For further information, visit the Iridex website at www.iridex.com.
Investor Relations Contact:
Philip Taylor
Gilmartin Group
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$1.26 |
| Daily Change: | -0.03 -2.33 |
| Daily Volume: | 810,182 |
| Market Cap: | US$21.160M |
May 13, 2025 April 14, 2025 January 14, 2025 | |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
